Ophthalmology Times: March 2022

According to review, patients with mild DR at baseline fare better

Severe ocular involvement demands inflammation control

Investigators find technology aids instruction of medical students

Device demonstrates potential as a durable, sustained-release glaucoma therapy

Despite inherent issues, clinicians still perform the procedure

Treatment options beginning to evolve from traditional therapies

Assembling a team of experts is key for diagnosis, treatment

Assessing cornea status can aid early recognition of disease-related changes

Lower doses vs higher ones are equally effective for treating disease

Provides safe, effective injection to target choroidal, retinal tissues

Drug is prescribed as adjunctive therapy for those with glaucoma

A team of investigators has found that nomacopan, a recombinant biologic derived from blood-feeding ticks, may be an option for the treatment of allergic eye disease due to its ability to down-regulate the LTB4/C5 pathways in experimental allergy conjunctivitis.

Physicians offer pearls to improve visualization in eyes using retroillumination techniques

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.